- U.S. Study MapU.S. Study Map overview
- Updates
- LearnWhat is a clinical study? Which is right for me? Learn about these and other questions in this section
- About
STRONG SCD
The STRONG SCD study is evaluating different dose levels of an oral investigational drug designed to lessen SCD complications, including pain crises.
30 US sites, 1 Lebanon site
16 to 70 years
SS, SC, Sβ0 thal, Sβ+ thal
Phase 2
SCTaware
This is a study for parents of infants with Sickle Cell Trait (SCT) identified by newborn screening who are referred and present for in-person SCT education at the Institution.
1 US site
18 to 65 years
AS (sickle cell trait)
Phase 1 / Phase 2
Sickle Cell and Bone Health
To determine whether having sickle cell trait (SCT) is a risk factor bone thinning at an earlier age and to understand why individuals with sickle cell disease (SCD) have thinner bones than healthy individuals do.
1 US site
18 to 45 years
SCD and SCT
N/A
January 14, 2021
BCH-BB694 — an experimental gene therapy targeting the BCL11A gene — safely increased the levels of fetal hemoglobin and prevented disease-associated complications in six people with severe sickle cell disease (SCD), according to interim data from a Phase 1 clinical trial.
January 10, 2021
When it comes to treating those with Sickle Cell Anemia, we found that we can match blood beyond type down to a certain antigen and it turns out that 33% of African American donors have this antigen in their blood and almost 0% Caucasion donors have the antigen.
January 5, 2021
In an effort to detect sea fan neovascularization from ultra-widefield color fundus photographs (UWF-FPs) from patients with sickle cell hemoglobinopathy (SCH), researchers developed an automated system with high sensitivity and specificity, which holds potential to improve screening for vision-threatening proliferative sickle cell retinopathy.
Sending updates featuring new studies and other relevant information about emerging sickle cell treatment options.